Astrazeneca (AZN) said Tuesday that baxdrostat has been accepted for priority review by the US Food and Drug Administration to treat adults with hard-to-control hypertension.

The submission was based on results from a phase 3 trial, which showed that the drug met the primary and all secondary endpoints, the company said.

The drugmaker said it expects a Prescription Drug User Fee Act action date during Q2 2026.